Post by RS Davis on Mar 12, 2004 13:04:08 GMT -5
[glow=red,2,300]Ilana Mercer Wrote:[/glow]Judging from the power-to-the-proletariat statements members of the jury issued after the trial of Martha Stewart and Peter Bacanovic, this jury was guided more by the spirit of Madame Defarge than Lady Justice. Missing only were the blood-thirsty character's knitting needles, although the jurors might as well have been knitting – they certainly did not grasp that Martha had not committed the non-crime of insider trading.
Chappell Hartridge, the juror who heralded this miscarriage of justice as a victory for the "little guy," followed up with yet another statement that ought to constitute grounds for an appeal: "We all knew in our hearts that the sale was based on Sam's actions." The perception that Ms. Stewart had been charged with insider trading – that she sold the fateful 3,928 ImClone shares after being tipped by insider and former ImClone CEO, Sam Waksal – clearly tainted the jury's verdict.
Ms. Stewart, however, had not been accused of insider trading. The government had not charged her with acting on information received from ImClone's Sam Waksal about the FDA's (demented) decision to refuse a Biologics Licensing Application for Waksal's promising cancer drug, Erbitux. It was not for lack of trying, mind you, but rather for a lack of evidence – while the government's case rested on an insider-trading investigation, the probe failed to prove that Ms. Stewart received material nonpublic information, or that Peter Bacanovic, her Merrill Lynch stockbroker, gave her such information. Furthermore, Ms. Stewart was not an "insider" in this instance – she sold the shares of a company to whose shareholders she had no fiduciary duty.
Chappell Hartridge, the juror who heralded this miscarriage of justice as a victory for the "little guy," followed up with yet another statement that ought to constitute grounds for an appeal: "We all knew in our hearts that the sale was based on Sam's actions." The perception that Ms. Stewart had been charged with insider trading – that she sold the fateful 3,928 ImClone shares after being tipped by insider and former ImClone CEO, Sam Waksal – clearly tainted the jury's verdict.
Ms. Stewart, however, had not been accused of insider trading. The government had not charged her with acting on information received from ImClone's Sam Waksal about the FDA's (demented) decision to refuse a Biologics Licensing Application for Waksal's promising cancer drug, Erbitux. It was not for lack of trying, mind you, but rather for a lack of evidence – while the government's case rested on an insider-trading investigation, the probe failed to prove that Ms. Stewart received material nonpublic information, or that Peter Bacanovic, her Merrill Lynch stockbroker, gave her such information. Furthermore, Ms. Stewart was not an "insider" in this instance – she sold the shares of a company to whose shareholders she had no fiduciary duty.
- Rick